艾伯维公司(ABBV)股价今日盘前大涨5.25%。这主要是因为该公司发布了2025年利润乐观预期,以及新型免疫药物Skyrizi和Rinvoq的销售前景良好。
具体来看,艾伯维预计2025年每股收益在12.12美元到12.32美元之间,超出分析师预期的12.18美元。同时,该公司上调Skyrizi和Rinvoq到2027年的合并销售额预期,从之前的270亿美元上调至310亿美元以上,反映出这两款新药的强大潜力。
再加上艾伯维2024年第四季度业绩出色,每股收益2.16美元超出预期,这进一步增强了市场对该公司长期增长前景的信心。尽管Humira销售遭受生物仿制药竞争的冲击,但新型免疫药物的强劲表现正有力弥补这一缺口,并为公司的未来发展注入新的动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.